← All issues  ·  The PepsRadar Weekly, November 16, 2026  ·  Got this from a friend? Get it free every Monday →
PepsRadar
PepsRadar
THE WEEKLY · NOV 2 – NOV 15
Peptide claims vs. the real studies. Here is what changed this week.
11
new guides
12
trial updates
1
FDA actions
 
Research field guide
Semaglutide not working? Why some people lose less, and what the trials show

Most people on semaglutide lose meaningful weight, but not everyone does. How many respond in the trials, why people with type 2 diabetes tend to lose less, what a new gene study found, and what the evidence says about switching or stopping.

Read the guide →
★ Trending on X this week
Semaglutide vs tirzepatide: what the head-to-head trials show
Only two randomized trials have compared semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) directly. Tirzepatide led to more weight loss in both. Here are the numbers, the side effects, the different…
Read it →
Glass research vials on a lab bench
For members
Member deals & codes →
This week's seller codes and announced sales, checked every Sunday and collected in your free members area.
More new on PepsRadar
Research field guide
Semaglutide and NAION: the FDA’s new vision warning, in numbers
On November 9, 2026 the FDA required every GLP-1 medicine, including semaglutide (Ozempic, Wegovy, Rybelsus), to carry a warning about NAION, a rare…
Research field guide
What happens when you stop semaglutide? What the trials show
In the trials, most people who stopped semaglutide (Ozempic, Wegovy) regained much of the weight within a year, and gains in blood pressure and blood…
Research field guide
Is ipamorelin legal? Side effects, FDA status and what the studies show
Ipamorelin is not an approved drug anywhere in the US, the FDA has flagged it as a compounding safety risk, and it was left out of the 2026 HHS…
Research field guide
Orforglipron (Foundayo): the GLP-1 pill, explained
Orforglipron (Foundayo) is a once-daily GLP-1 pill the FDA approved for weight loss in April 2026. What it is, why it isn’t a peptide, what the ATTAIN…
Research field guide
When will retatrutide be approved? Where Lilly’s FDA application stands
Retatrutide is not approved anywhere yet. Eli Lilly says it plans to submit it to the FDA in the first quarter of 2027. How long FDA review usually…
Research field guide
Mitochondrial peptides: what MOTS-c, humanin and SS-31 (elamipretide) actually show in people
MOTS-c and humanin are made by mitochondria; elamipretide (SS-31) is a drug aimed at them. Mouse data and blood-level studies back the first two; only…
Research field guide
Tissue repair peptides: which have actually been tested in people?
A roundup of popular tissue repair peptides and what has been tested in people: BPC-157's tiny human record, thymosin beta-4 eye and ulcer trials…
Research field guide
The Wegovy pill vs Foundayo: the two GLP-1 weight-loss pills compared
The Wegovy pill (oral semaglutide) and Foundayo (orforglipron) are the two FDA-approved GLP-1 pills for weight loss. How they differ as drugs, how…
Research field guide
GLP-1 side effects compared: semaglutide, tirzepatide, retatrutide and orforglipron
Stomach and gut problems topped the side-effect list in the main obesity trials of all four drugs. What STEP 1, SURMOUNT-1, TRIUMPH-1 and ATTAIN-1…
Research field guide
CagriSema: where Novo Nordisk's cagrilintide combination stands
CagriSema pairs cagrilintide, a long-acting amylin analogue, with semaglutide in one weekly shot. It cut weight about 20% in its main trial, trailed…
Clinical trial updates
From our weekly ClinicalTrials.gov checks. A registration is a plan, not a result.
Status changeUBT251Phase 3active, not recruiting
New studySemaglutidePhase 2 / Phase 3not yet recruiting
See all 12 trial updates in the tracker →
FDA and regulatory
November 9, 2026
Dulaglutide, Exenatide, Liraglutide and 4 more: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine.
Our trackers
Clinical trial tracker
registered human studies, re-checked weekly
Regulatory tracker
FDA, compounding and anti-doping status
Claim checks
popular claims tested against the studies
Know someone who'd want this? Forward this email, or send them to pepsradar.com/newsletter to sign up free with just an email address.

For research and education only. PepsRadar summarizes published research and public records; it is not medical advice, has not been reviewed by a medical professional, and never gives dosing instructions. The member deals link opens PepsRadar's members area, where seller links may be affiliate links and PepsRadar may earn a commission. This email names no sellers or products.

Got this from a friend? Get the PepsRadar Weekly free every Monday: sign up with just your email.